medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 1

<< Back Next >>

Med Int Mex 2020; 36 (1)

Obesity and diabetes, interconnected diseases

Córdova-Pluma VH, Vega-López CA, Ortega-Chavarría MJ, Mellado-Orellana R

Language: Spanish
References: 38
Page: 77-82
PDF size: 195.46 Kb.


ABSTRACT

Due to the high prevalence of diabetes mellitus type 2, this has become a health problem around the world. At present the involvement of the obesity is known as the most important risk factor for its development, keeping in mind that even in patients with normal weight, a high percentage of body fat can be found. The change in hygienic dietetic habits are interventions directed to prevention and treatment. The choice of pharmacologic treatment should consider control of the muscle/fat relationship for the control of body weight. Bariatric surgery is indicated in patients with IMC › 35 kg/m2 with associated risk factors, highlighting the partial remission shown after the treatment, with long term studies being necessary of its benefic effects after the procedure. Due to the importance of these illnesses a review of the subject is made.


REFERENCES

  1. Instituto Nacional de Salud Pública. ENSANUT MC 2016. Informe Final de Resultados. Disponible en: http://promocion. salud.gob.mx/dgps/descargas1/

  2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med 2007;356(3):213-5. DOI: 10.1056/NEJMp068177.

  3. International Diabetes Federation Diabetes Atlas. 2ed. Brussels, International Diabetes Federation. 2003. http:// www.diabetesatlas.org/component/attachments. Zugegriffen: 28. Sept 2017.

  4. Oldridge NB, et al. Prevalence and outcomes of comorbid metaboic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol 2001;54(9):928-34. DOI: 10.1016/s0895-4356(01)00350-x.

  5. Kelly T, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008; 32(9):1431-7. doi: 10.1038/ijo.2008.102.

  6. WHO. Obesity and overweight fact sheet no. 311. 2016. http://who.int/mediacentre/factsheets/fs311/en/. Zugegriffen: 28.Sept.2017.

  7. Prospective Studies Collaboration, et al. Body-mass index and cause specific mortality in 900 000 adults: collaborative analyse of 57 prospective studies. Lancet 2009;373(9669):1083-96. DOI:https://doi.org/10.1016/ S0140-6736(09)60318-4.

  8. Hebebrand J, et al. A proposal of the European Association for the Study of Obesity to improve the ICD-11 diagnostic criteria for obesity based in the three dimensions etiology, degree of adiposity and health risk. Obes Facts 2017;10(4):284-307. doi: 10.1159/000479208.

  9. Gomez-Ambrosi J, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors relatead to elevated adiposity. Int J Obes (Lond) 2012.;36(2):286-94. doi: 10.1038/ijo.2011.100.

  10. Goodpaster BH, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059-64. https://doi.org/10.1093/gerona/ 61.10.1059.

  11. Cruz-Jentoft AJ, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. doi: 10.1093/ageing/afq034.

  12. Malmstrom TK, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016;7(1):28-36. doi: 10.1002/jcsm.12048.

  13. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and interventionstrategies. Lancet 2004;363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3.

  14. Tsigos C, et al. Management of obesity in adults: European clinicalpracticeguidelines. Obes Facts 2008;1(2):106-16. doi: 10.1159/000126822.

  15. Grebitus C, Hartmann M, Reynolds N. Global obesity study on drivers for weight reduction strategies. Obes Facts 2015;8(1):77-86. http://dx.doi.org/10.1159%2F000373905.

  16. Yumuk V, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721.

  17. Krebs JD, et al. The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. Diabetologia 2012;55(4):905-14. doi: 10.1007/s00125- 012-2461-0.

  18. Esposito K, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009;151(5):306-14. DOI: 10.7326/0003- 4819-151-5-200909010-00004.

  19. Wadden TA, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) 2009;17(4):713-22. doi:10.1038/oby.2008.637.

  20. Cawthorn P, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc 2009;57(8):1411- 9. doi: 10.1111/j.1532-5415.2009.02366.x.

  21. Dansinger ML, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53. DOI: 10.1001/jama.293.1.43.

  22. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

  23. Lean ME, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7(3):228-33. DOI: 10.1111/ j.1464-5491.1990.tb01375.x.

  24. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170(17):1566-75. doi: 10.1001/archinternmed. 2010.334.

  25. Rubin RR, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544- 53. doi: 10.2337/dc13-1928.

  26. Leitner DR, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO Can Lead the Way. Obes Facts 2017;10(5):483-92. doi: 10.1159/000480525. Epub 2017 Oct 12.

  27. Zidek W, et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol 2008;7:22. doi: 10.1186/1475-2840-7-22.

  28. Toplak H, et al. 2014 EASO position statement on the use of anti-obesitydrugs. Obes Facts 2015;8(3):166-74. DOI: 10.1159/000430801.

  29. Sjöström L, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351(26):2683-93. DOI: 10.1056/NEJMoa035622.

  30. Neovius M, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308(11):1132-41. DOI: 10.1001/2012.jama.11792.

  31. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273(3):219-34. doi: 10.1111/joim.12012.

  32. Thibault R, et al. Twelve key nutritional issues in bariatric surgery. Clin Nutr. 2016;35(1):12-7. doi: 10.1016/j. clnu.2015.02.012.

  33. Busetto L, et al. Practical recommendations of the obesity management task force of the European association for the study of obesity for the post-bariatric surgery medical management. Obes Facts. 2017;10(6):597-632. doi: 10.1159/000481825.

  34. Sjöholm K, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015;58(7):1448-53. doi: 10.1007/ s00125-015-3591-y.

  35. Rubino F, etal. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016;39(6):861-77. https://doi.org/10.2337/dc16-0236.

  36. Schauer PR, Nor Hanipah Z, Rubino F. Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world’s leading diabetes organizations. Cleve Clin J Med 2017;84(7 Suppl 1):S47-S56. doi: 10.3949/ccjm.84. s1.06.

  37. Buchwald H, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248-256e5. doi: 10.1016/j.amjmed. 2008.09.041.

  38. Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 2017;376(7):641-51. DOI: 10.1056/NEJMoa1600869.




2020     |     www.medigraphic.com